Headlands Technologies LLC Acquires 1,338 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Headlands Technologies LLC lifted its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 397.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,675 shares of the medical research company’s stock after buying an additional 1,338 shares during the period. Headlands Technologies LLC’s holdings in IQVIA were worth $329,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in IQV. Synergy Asset Management LLC purchased a new stake in IQVIA during the fourth quarter valued at approximately $33,000. Lee Danner & Bass Inc. purchased a new position in IQVIA during the fourth quarter worth $44,000. Zions Bancorporation N.A. increased its position in IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 85 shares during the last quarter. Versant Capital Management Inc raised its stake in shares of IQVIA by 46.0% in the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock valued at $58,000 after acquiring an additional 93 shares during the period. Finally, SBI Securities Co. Ltd. purchased a new position in shares of IQVIA during the 4th quarter worth about $60,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

IQV opened at $154.63 on Friday. The firm has a market capitalization of $27.26 billion, a PE ratio of 20.62, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46. The business’s 50-day moving average is $189.67 and its two-hundred day moving average is $204.07. IQVIA Holdings Inc. has a 1 year low of $154.35 and a 1 year high of $252.88. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Research analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have issued reports on IQV shares. JPMorgan Chase & Co. decreased their price objective on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a research note on Tuesday, February 18th. Stifel Nicolaus dropped their price objective on IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a report on Friday, February 7th. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a research note on Wednesday, March 12th. Barclays lowered their target price on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research note on Monday, February 3rd. Finally, Citigroup decreased their price objective on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Five analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $249.05.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.